Jaguar Health Appoints Industry Veteran to Lead Sales for Oncology and HIV Products

Jaguar Health, Inc. has appointed Susan Krizancic as the National Sales Director for its subsidiary, Napo Pharmaceuticals. The company aims to enhance the sales of its oncology and HIV products, including the upcoming launch of Gelclair in October 2024.

Susan Krizancic brings 30 years of experience in the biopharmaceutical sector, with recent roles focused on oncology. Her previous positions at Mirati Therapeutics and AstraZeneca demonstrate a strong background in sales and team leadership.

Jaguar Health's CEO Lisa Conte expressed confidence in Krizancic's ability to drive sales and meet the needs of patients dealing with complex disease states such as cancer and HIV.

In her new role, Krizancic will be instrumental in the commercial launch of Gelclair, an FDA-approved product for managing pain associated with oral mucositis, and will oversee the sales strategies for other FDA-approved prescription products.